Aalberts: highlights ING Benelux Conference Brussels 2024, Ackermans & Van Haaren: Highlights ING Benelux Conference Brussels,Ackermans & Van Haaren: Strong operational performance of underlying companies and guidance fine-tuned upwards, AMG: Highlights ING Benelux Conference Brussels, Aperam: Highlights ING Benelux Conference Brussels, Arcadis: Highlights ING Benelux conference, Azelis: Highlights ING Benelux Conference Brussels, Bekaert: Guidance cut and €200m buyback as sweetener, CFE: No new...
UCB has received a 5th nod for Bimzelx as hidradenitis suppurativa joins the fray of approved indications. We see an important role for Bimzelx in this emerging disease space with clear potential to become standard of care over time given its clear outperformance over Novartis' Cosentyx in the clinic. We reiterate our € 173 TP and Accumulate rating.
UCB shared first insights into the Phase 3 data on dapimap in SLE, which appear generally favourable with a 14.6% BICLA benefit after 48 weeks vs. SoC. The data also shows a steroid tapering effect and reduction in flares, while suggesting possible outperformance vs. current market leader Benlysta (GSK). Dapimap is co-developed with Biogen and will be continued in a second Ph3 study. We reiterate our € 173 TP and Accumulate rating.
Ageas reports on the progress of share buy-back programme Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 129,096 Ageas shares in the period from 11-11-2024 until 15-11-2024. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)11-11-202421,0001,016,27948.3948.2448.5212-11-202434,1711,640,90848.0247.9048.4413-11-202442,1501,993,54647.3046.8647.6614-11-202426,1991,255,60047.9347.5448.1615-11-20245,576269,93748.4147.9648.66Total12...
Rapport d’Ageas sur le programme de rachat d’actions Rapport d’Ageas sur le programme de rachat d’actions Dans le cadre du programme de rachat d’actions annoncé le 28 août 2024, Ageas indique que 129.096 actions Ageas ont été achetées durant la période du 11-11-2024 au 15-11-2024. DateNombred’actionsMontant total(EUR)Cours moyen(EUR)Cours le plus bas (EUR)Cours le plus élevé (EUR)11-11-202421.0001.016.27948,3948,2448,5212-11-202434.1711.640.90848,0247,9048,4413-11-202442.1501.993.54647,3046,8647,6614-11-202426.1991.255.60047,9347,5448,1615-11-20245.576269.93748,4147,9648,66Total129.0966.17...
Ageas rapporteert over de inkoop van eigen aandelen Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 129.096 eigen aandelen ingekocht werden tussen 11-11-2024 en 15-11-2024. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)11-11-202421.0001.016.27948,3948,2448,5212-11-202434.1711.640.90848,0247,9048,4413-11-202442.1501.993.54647,3046,8647,6614-11-202426.1991.255.60047,9347,5448,1615-11-20245.576269.93748,4147,9648,66Totaal129....
Ageas and Amundi SA: Transparency notification Ageas and Amundi SA: Transparency notification In accordance with the rules on financial transparency*, Amundi SA has notified Ageas on 12 November 2024 that, on 8 November 2024, its interest has fallen below the statutory threshold of 3% of the shares issued by Ageas. Its current shareholding stands at 2.53%. Reason for the notificationAcquisition or disposal of voting securities or voting rights Downward crossing of the lowest threshold Notification byA parent undertaking or a controlling person Persons subject to the notification requir...
Ageas et Amundi SA: Notification de transparence Ageas et Amundi SA: Notification de transparence Conformément aux règles de transparence financière*, Amundi SA a introduit le 12 novembre 2024 une notification annonçant que, le 8 novembre 2024 sa participation a franchi, à la baisse, le seuil statutaire de 3% des actions émises par Ageas et atteint 2,53%. Motif de la notificationAcquisition ou cession de titres conférant le droit de vote ou de droits de voteFranchissement vers le bas du seuil minimumNotification parUne entreprise mère ou une personne détenant le contrôle Personne(s) tenu...
Ageas en Amundi SA: Transparantiekennisgeving Ageas en Amundi SA: Transparantiekennisgeving Amundi SA informeerde Ageas op 12 november 2024, overeenkomstig de financiële transparantievereisten*, dat zijn belang op 8 november 2024 onder de statutaire drempel van 3% van de door Ageas uitgegeven aandelen is gedaald en nu 2,53% bedraagt. Reden van de kennisgevingVerwerving of overdracht van stemrechtverlenende effecten of stemrechtenOnderschrijding van de laagste drempelKennisgeving doorEen moederonderneming of een controlerende persoon Kennisgevingsplichtige perso(o)n(en)Zie bijlage 1a. Da...
Agfa-Geveart: Material miss on Healthcare activities. ASML: Long-term guidance confirmed. CVC Capital Partners: Comfortably on track. DEME Group: Raises outlook, lowers capex guidance. Proximus: Pressure on CEO from another possible coalition party. SBM Offshore: Again delivering
We maintain our Outperform rating on CaixaBank, one of our Top Picks in the sector, with a higher target of € 7.2 vs € 6.7 and ahead of the CMD on 19 November. We are lifting our net income estimates by 7% for 2025-2026, to 7% above the consensus. The strategic update is set to highlight the wisdom of the business model diversification (long-term savings) to address the current transition phase on rates. Despite a solid market performance, the profile does not look to be fully reflec...
Nous réitérons notre opinion Surperformance sur CaixaBank, l’un de nos top picks du secteur, avec un OC porté à 7.2 € vs 6.7 € et en amont du CMD du 19/11. Nous relevons nos anticipations de RN de 7% sur 2025/2026 qui ressortent 7% supérieures au consensus. L’update stratégique devrait mettre en avant la pertinence de la diversification du business model (épargne LT) face à la transition actuelle sur les taux. Malgré un solide parcours boursier, cela n’est pas pleinement reflété dans ...
>PSOE and Sumar spring a surprise in seeking to suddenly abolish the SOCIMI regime - On Monday 11 November, the PSOE reached a tax agreement with its Spanish government ally, “Sumar”, whereby the two parties want to abolish the SOCIMI REIT regime or at least part of its tax advantages. This sudden stance, which surprised Spanish property professionals, is thus different from the position that was presented just last week, namely to “encourage the construction of affor...
>PSOE et Sumar créent la surprise en voulant supprimer soudainement le régime SOCIMI - Ce lundi 11 novembre, le PSOE sont parvenus à un accord fiscal avec son allié au gouvernement espagnol, « Sumar », par lequel les deux partis veulent supprimer le régime SOCIMI ou au moins une partie de ses avantages fiscaux. Cette prise de position soudaine qui a crée la surprise auprès des professionnels de l’immobilier espagnol, diffère ainsi de la position qui était encore mise ...
We reiterate our BUY rating on UCB and increase our target price from €180 to €212. After almost a year on the ING Benelux Favourites List, we believe it is an opportune time to remove UCB as we view our upside as more risky than in the past as it is increasingly weighted towards UCB's development pipeline. Nonetheless, we remain confident in UCB's equity story, driven by INGF €6bn peak sales for Bimzelx, a continued strong performance of secondary growth engines Evenity and Rystiggo, as well as...
Ageas reports on the progress of share buy-back programme Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 114,483 Ageas shares in the period from 04-11-2024 until 08-11-2024. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)04-11-202421,5461,038,22448.1948.1048.4005-11-202420,9611,016,94248.5248.1848.7806-11-202421,5531,048,64248.6548.0849.3407-11-202424,3471,181,94348.5548.1848.9408-11-202426,0761,253,57148.0748.2648.52Tota...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.